ReviewIUBMB life2026

Half-Life as a Therapeutic Design Axis: Targeting Short-Lived lncRNAs With Antisense Oligonucleotides.

Hidenori TaniPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.